<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37700026</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Gene signature from cutaneous autoimmune diseases provides potential immunotherapy-relevant biomarkers in melanoma.</ArticleTitle><Pagination><StartPage>15023</StartPage><MedlinePgn>15023</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15023</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-42238-3</ELocationID><Abstract><AbstractText>Immune checkpoint inhibitors (ICIs) are promising agents for treating melanoma. Given that autoimmune skin diseases exhibit hyper immune reaction, investigation of immune cells from autoimmune skin disease is crucial to validate the effectiveness of ICIs in melanoma treatment. We employed multipanel markers to predict the response to immune checkpoint inhibitors by characterizing the gene expression signatures of skin immune cells in systemic lupus erythematosus (SLE), atopic dermatitis (AD), and psoriasis (PS). By analyzing single-cell RNA sequencing data from each dataset, T cell gene signatures from autoimmune skin diseases exhibit a complex immune response in tumors that responded to immunotherapy. Based on that CD86 and CD80 provide essential costimulatory signals for T cell activation, we observed that interaction of CD86 signaling has been enhanced in the T cells of patients with SLE, AD, and PS. Our analysis revealed a common increase in CD86 signals from dendritic cells (DCs) to T cells in patients with SLE, AD, and PS, confirming that dendritic cells produce pro-inflammatory cytokines to activate T cells. Thus, we hypothesize that T cell gene signatures from autoimmune skin diseases exhibit a pro-inflammatory response and have the potential to predict cancer immunotherapy. Our study demonstrated that T cell gene signatures derived from inflammatory skin diseases, particularly SLE and PS, hold promise as potential biomarkers for predicting the response to immune checkpoint blockade therapy in patients with melanoma. Our data provide an understanding of the immune-related characteristics and differential gene expression patterns in autoimmune skin diseases, which may represent promising targets for melanoma immunotherapy.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chun</LastName><ForeName>Kyu-Hye</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Seoul, 03722, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chronic Intractable Disease for Systems Medicine Research Center, Yonsei University College of Medicine, Seoul, 03722, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Park</LastName><ForeName>Ye-Chan</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Severance Biomedical Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Nahee</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Seoul, 03722, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chronic Intractable Disease for Systems Medicine Research Center, Yonsei University College of Medicine, Seoul, 03722, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Bo Kyung</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Seoul, 03722, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chronic Intractable Disease for Systems Medicine Research Center, Yonsei University College of Medicine, Seoul, 03722, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Seoul, 03722, Korea. japol13@yuhs.ac.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chronic Intractable Disease for Systems Medicine Research Center, Yonsei University College of Medicine, Seoul, 03722, Korea. japol13@yuhs.ac.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Sungsoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Korea. sfang@yuhs.ac.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chronic Intractable Disease for Systems Medicine Research Center, Yonsei University College of Medicine, Seoul, 03722, Korea. sfang@yuhs.ac.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Severance Biomedical Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Korea. sfang@yuhs.ac.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>27307C0012</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012871" MajorTopicYN="Y">Skin Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011565" MajorTopicYN="Y">Psoriasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003876" MajorTopicYN="Y">Dermatitis, Atopic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37700026</ArticleId><ArticleId IdType="pmc">PMC10497583</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-42238-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-42238-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang J, Cui B, Chen Z, Ding X. The regulation of skin homeostasis, repair and the pathogenesis of skin diseases by spatiotemporal activation of epidermal mTOR signaling. Front. Cell Dev. Biol. 2022 doi: 10.3389/fcell.2022.950973.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.950973</ArticleId><ArticleId IdType="pmc">PMC9355246</ArticleId><ArticleId IdType="pubmed">35938153</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanpain C, Fuchs E. Epidermal homeostasis: A balancing act of stem cells in the skin. Nat. Rev. Mol. Cell Biol. 2009;10:207&#x2013;217. doi: 10.1038/nrm2636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2636</ArticleId><ArticleId IdType="pmc">PMC2760218</ArticleId><ArticleId IdType="pubmed">19209183</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DH, Chang DM, Lai JH, Lin FH, Chen CH. Significantly higher percentage of circulating CD27(high) plasma cells in systemic lupus erythematosus patients with infection than with disease flare-up. Yonsei Med. J. 2010;51:924&#x2013;931. doi: 10.3349/ymj.2010.51.6.924.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2010.51.6.924</ArticleId><ArticleId IdType="pmc">PMC2995985</ArticleId><ArticleId IdType="pubmed">20879061</ArticleId></ArticleIdList></Reference><Reference><Citation>Acevedo N, et al. Epigenetic alterations in skin homing CD4+CLA+ T cells of atopic dermatitis patients. Sci. Rep. 2020;10:18020. doi: 10.1038/s41598-020-74798-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-74798-z</ArticleId><ArticleId IdType="pmc">PMC7582180</ArticleId><ArticleId IdType="pubmed">33093567</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med. J. 2006;47:293&#x2013;306. doi: 10.3349/ymj.2006.47.3.293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2006.47.3.293</ArticleId><ArticleId IdType="pmc">PMC2688147</ArticleId><ArticleId IdType="pubmed">16807977</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J. Pediatr. 2020;16:19&#x2013;30. doi: 10.1007/s12519-019-00229-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-019-00229-3</ArticleId><ArticleId IdType="pmc">PMC7040062</ArticleId><ArticleId IdType="pubmed">30796732</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016;387:1109&#x2013;1122. doi: 10.1016/S0140-6736(15)00149-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00149-X</ArticleId><ArticleId IdType="pubmed">26377142</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano M, di Vico F, Ruggiero A, Fabbrocini G, Patruno C. The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis. Front. Med. 2023 doi: 10.3389/fmed.2023.1165098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1165098</ArticleId><ArticleId IdType="pmc">PMC10151557</ArticleId><ArticleId IdType="pubmed">37144036</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung DYM, Berdyshev E, Goleva E. Cutaneous barrier dysfunction in allergic diseases. J. Allergy Clin. Immunol. 2020;145:1485&#x2013;1497. doi: 10.1016/j.jaci.2020.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.02.021</ArticleId><ArticleId IdType="pmc">PMC7291847</ArticleId><ArticleId IdType="pubmed">32507227</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedoszytko B, et al. Pathogenesis of psoriasis in the "omic" era. Part II. Genetic, genomic and epigenetic changes in psoriasis. Postepy Dermatol. Alergol. 2020;37:283&#x2013;298. doi: 10.5114/ada.2020.96243.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ada.2020.96243</ArticleId><ArticleId IdType="pmc">PMC7394158</ArticleId><ArticleId IdType="pubmed">32774210</ArticleId></ArticleIdList></Reference><Reference><Citation>Rendon A, Sch&#xe4;kel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 2019 doi: 10.3390/ijms20061475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061475</ArticleId><ArticleId IdType="pmc">PMC6471628</ArticleId><ArticleId IdType="pubmed">30909615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu P, et al. The role of helper T cells in psoriasis. Front. Immunol. 2021 doi: 10.3389/fimmu.2021.788940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.788940</ArticleId><ArticleId IdType="pmc">PMC8714744</ArticleId><ArticleId IdType="pubmed">34975883</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon S, Jang YK, Shin JU, Kim DH, Lee HJ. Innate Immunity protein markers are significantly elevated in hidradenitis suppurativa skin than in psoriasis vulgaris. Yonsei Med. J. 2022;63:971&#x2013;973. doi: 10.3349/ymj.2022.0160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2022.0160</ArticleId><ArticleId IdType="pmc">PMC9520045</ArticleId><ArticleId IdType="pubmed">36168251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowes MA, Su&#xe1;rez-Fari&#xf1;as M, Krueger JG. Immunology of psoriasis. Annu. Rev. Immunol. 2014;32:227&#x2013;255. doi: 10.1146/annurev-immunol-032713-120225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120225</ArticleId><ArticleId IdType="pmc">PMC4229247</ArticleId><ArticleId IdType="pubmed">24655295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell. 1995;82:13&#x2013;17. doi: 10.1016/0092-8674(95)90047-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90047-0</ArticleId><ArticleId IdType="pubmed">7606778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocheva GS, Slominski RM, Slominski AT. Immunological aspects of skin aging in atopic dermatitis. Int. J. Mol. Sci. 2021;22:5729. doi: 10.3390/ijms22115729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115729</ArticleId><ArticleId IdType="pmc">PMC8198400</ArticleId><ArticleId IdType="pubmed">34072076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiravand Y, et al. Immune checkpoint inhibitors in cancer therapy. Curr. Oncol. 2022;29:3044&#x2013;3060. doi: 10.3390/curroncol29050247.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol29050247</ArticleId><ArticleId IdType="pmc">PMC9139602</ArticleId><ArticleId IdType="pubmed">35621637</ArticleId></ArticleIdList></Reference><Reference><Citation>Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366:2443&#x2013;2454. doi: 10.1056/NEJMoa1200690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId><ArticleId IdType="pmc">PMC3544539</ArticleId><ArticleId IdType="pubmed">22658127</ArticleId></ArticleIdList></Reference><Reference><Citation>Billi AC, et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci. Transl. Med. 2022;14:eabn2263. doi: 10.1126/scitranslmed.abn2263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn2263</ArticleId><ArticleId IdType="pmc">PMC9169615</ArticleId><ArticleId IdType="pubmed">35476593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rindler K, et al. Spontaneously resolved atopic dermatitis shows melanocyte and immune cell activation distinct from healthy control skin. Front. Immunol. 2021;12:630892. doi: 10.3389/fimmu.2021.630892.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.630892</ArticleId><ArticleId IdType="pmc">PMC7943477</ArticleId><ArticleId IdType="pubmed">33717163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, et al. Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets. J. Allergy Clin. Immunol. 2021;148:1281&#x2013;1292. doi: 10.1016/j.jaci.2021.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.04.021</ArticleId><ArticleId IdType="pmc">PMC8553817</ArticleId><ArticleId IdType="pubmed">33932468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C, Satija R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 2019;20:296. doi: 10.1186/s13059-019-1874-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1874-1</ArticleId><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573&#x2013;3587.e3529. doi: 10.1016/j.cell.2021.04.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.048</ArticleId><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky I, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods. 2019;16:1289&#x2013;1296. doi: 10.1038/s41592-019-0619-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0619-0</ArticleId><ArticleId IdType="pmc">PMC6884693</ArticleId><ArticleId IdType="pubmed">31740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, et al. Gene ontology: Tool for the unification of biology. Nat. Genet. 2000;25:25&#x2013;29. doi: 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S, Castelo R, Guinney J. GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinf. 2013;14:7. doi: 10.1186/1471-2105-14-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-7</ArticleId><ArticleId IdType="pmc">PMC3618321</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortekaas Krohn I, et al. T-cell subsets in the skin and their role in inflammatory skin disorders. Allergy. 2022;77:827&#x2013;842. doi: 10.1111/all.15104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15104</ArticleId><ArticleId IdType="pubmed">34559894</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Shi Y, Zou Y. T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis. Front. Immunol. 2023 doi: 10.3389/fimmu.2023.1081999.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1081999</ArticleId><ArticleId IdType="pmc">PMC10040887</ArticleId><ArticleId IdType="pubmed">36993982</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen CTH, et al. Up-regulated expression of CD86 on circulating intermediate monocytes correlated with disease severity in psoriasis. J. Dermatol. Sci. 2018;90:135&#x2013;143. doi: 10.1016/j.jdermsci.2018.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdermsci.2018.01.005</ArticleId><ArticleId IdType="pubmed">29395574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bour-Jordan H, et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol. Rev. 2011;241:180&#x2013;205. doi: 10.1111/j.1600-065X.2011.01011.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2011.01011.x</ArticleId><ArticleId IdType="pmc">PMC3077803</ArticleId><ArticleId IdType="pubmed">21488898</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JL, et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 1996;271:26762&#x2013;26771. doi: 10.1074/jbc.271.43.26762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.43.26762</ArticleId><ArticleId IdType="pubmed">8900156</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkun Y, et al. Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus. Eur. J. Immunol. 2008;38:2896&#x2013;2904. doi: 10.1002/eji.200838342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200838342</ArticleId><ArticleId IdType="pubmed">18958888</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuller E, et al. In situ expression of the costimulatory molecules CD80 and CD86 on langerhans cells and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis. Arch. Dermatol. Res. 2001;293:448&#x2013;454. doi: 10.1007/s004030100263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004030100263</ArticleId><ArticleId IdType="pubmed">11758787</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohki O, et al. Functional CD86 (B7&#x2013;2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis. Br. J. Dermatol. 1997;136:838&#x2013;845. doi: 10.1046/j.1365-2133.1997.01836.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2133.1997.01836.x</ArticleId><ArticleId IdType="pubmed">9217814</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra RS, Judge TA, Nestle FO, Turka LA, Nickoloff BJ. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7&#x2013;1 (CD80) and B7&#x2013;2 (CD86) expression. J. Immunol. 1995;154:2668&#x2013;2677. doi: 10.4049/jimmunol.154.6.2668.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.154.6.2668</ArticleId><ArticleId IdType="pubmed">7533180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf SJ, et al. Ultraviolet light induces increased T cell activation in lupus-prone mice via type I IFN-dependent inhibition of T regulatory cells. J. Autoimmun. 2019;103:102291. doi: 10.1016/j.jaut.2019.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.06.002</ArticleId><ArticleId IdType="pmc">PMC6708464</ArticleId><ArticleId IdType="pubmed">31248690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B, et al. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 2008;58:801&#x2013;812. doi: 10.1002/art.23268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23268</ArticleId><ArticleId IdType="pubmed">18311820</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-&#x3b1; systemic lupus erythematosus. Science. 2001;294:1540&#x2013;1543. doi: 10.1126/science.1064890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1064890</ArticleId><ArticleId IdType="pubmed">11711679</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangou EA, Bertsias GK, Boumpas DT. Gene expression and regulation in systemic lupus erythematosus. Eur. J. Clin. Invest. 2013;43:1084&#x2013;1096. doi: 10.1111/eci.12130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.12130</ArticleId><ArticleId IdType="pubmed">23902282</ArticleId></ArticleIdList></Reference><Reference><Citation>Demers-Mathieu V. Optimal selection of IFN-&amp;alpha;-inducible genes to determine type I interferon signature improves the diagnosis of systemic lupus erythematosus. Biomedicines. 2023;11:864. doi: 10.3390/biomedicines11030864.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11030864</ArticleId><ArticleId IdType="pmc">PMC10045398</ArticleId><ArticleId IdType="pubmed">36979843</ArticleId></ArticleIdList></Reference><Reference><Citation>Reefer AJ, et al. Analysis of CD25hiCD4+ &#x201c;regulatory&#x201d; T-cell subtypes in atopic dermatitis reveals a novel TH2-like population. J. Allergy Clin. Immunol. 2008;121:415&#x2013;422.e413. doi: 10.1016/j.jaci.2007.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2007.11.003</ArticleId><ArticleId IdType="pubmed">18177697</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, et al. DAMP molecules S100A9 and S100A8 activated by IL-17A and house-dust mites are increased in atopic dermatitis. Exp. Dermatol. 2014;23:938&#x2013;941. doi: 10.1111/exd.12563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.12563</ArticleId><ArticleId IdType="pubmed">25308296</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesko B, et al. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med. Genomics. 2010;3:15. doi: 10.1186/1755-8794-3-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1755-8794-3-15</ArticleId><ArticleId IdType="pmc">PMC2874757</ArticleId><ArticleId IdType="pubmed">20444268</ArticleId></ArticleIdList></Reference><Reference><Citation>Synn C-B, et al. primary tumor suppression and systemic immune activation of macrophages through the sting pathway in metastatic skin tumor. Yonsei Med. J. 2022;63:42&#x2013;55. doi: 10.3349/ymj.2022.63.1.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2022.63.1.42</ArticleId><ArticleId IdType="pmc">PMC8688365</ArticleId><ArticleId IdType="pubmed">34913283</ArticleId></ArticleIdList></Reference><Reference><Citation>Slominski RM, et al. Melanoma, melanin, and melanogenesis: The Yin and Yang relationship. Front. Oncol. 2022 doi: 10.3389/fonc.2022.842496.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.842496</ArticleId><ArticleId IdType="pmc">PMC8963986</ArticleId><ArticleId IdType="pubmed">35359389</ArticleId></ArticleIdList></Reference><Reference><Citation>Slominski RM, Raman C, Chen JY, Slominski AT. How cancer hijacks the body&#x2019;s homeostasis through the neuroendocrine system. Trends Neurosci. 2023;46:263&#x2013;275. doi: 10.1016/j.tins.2023.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2023.01.003</ArticleId><ArticleId IdType="pmc">PMC10038913</ArticleId><ArticleId IdType="pubmed">36803800</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai H-F, Hsu P-N. Cancer immunotherapy by targeting immune checkpoints: Mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. J. Biomed. Sci. 2017;24:35. doi: 10.1186/s12929-017-0341-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-017-0341-0</ArticleId><ArticleId IdType="pmc">PMC5445514</ArticleId><ArticleId IdType="pubmed">28545567</ArticleId></ArticleIdList></Reference><Reference><Citation>Paluch C, Santos AM, Anzilotti C, Cornall RJ, Davis SJ. Immune checkpoints as therapeutic targets in autoimmunity. Front. Immunol. 2018 doi: 10.3389/fimmu.2018.02306.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02306</ArticleId><ArticleId IdType="pmc">PMC6186808</ArticleId><ArticleId IdType="pubmed">30349540</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 2022;19:775&#x2013;790. doi: 10.1038/s41571-022-00689-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-022-00689-z</ArticleId><ArticleId IdType="pubmed">36216928</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone DP, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 2017;376:2415&#x2013;2426. doi: 10.1056/NEJMoa1613493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1613493</ArticleId><ArticleId IdType="pmc">PMC6487310</ArticleId><ArticleId IdType="pubmed">28636851</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124&#x2013;128. doi: 10.1126/science.aaa1348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa1348</ArticleId><ArticleId IdType="pmc">PMC4993154</ArticleId><ArticleId IdType="pubmed">25765070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wculek SK, et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 2020;20:7&#x2013;24. doi: 10.1038/s41577-019-0210-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0210-z</ArticleId><ArticleId IdType="pubmed">31467405</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JA, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 2003;170:1257&#x2013;1266. doi: 10.4049/jimmunol.170.3.1257.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.3.1257</ArticleId><ArticleId IdType="pubmed">12538684</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 2003;3:544&#x2013;556. doi: 10.1038/nri1131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1131</ArticleId><ArticleId IdType="pubmed">12876557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>